Research Article
Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
Table 1
The baseline demographic data.
| ||||||||||||||||||||||||||||||||||||||||||||||||
RMAB group: rabeprazole plus minocycline, amoxicillin, and bismuth; RMMB group: rabeprazole plus minocycline, metronidazole, and bismuth; RACB group: rabeprazole plus amoxicillin, clarithromycin, and bismuth. BMI: body mass index. |